Aaron M Drucker, MD, ScM, FRCPC, FAAD
Disclosures
Drucker reports no relevant financial disclosures.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.The pipeline for atopic dermatitis are a number of different biologic and small molecule agents. We've had a few biologics approved since 2017 when dupilumab (Dupixent; Sanofi, Regeneron) was approved and also oral JAK inhibitors, and there have been a few approved since then. I think what a lot of us are really looking forward to are some new biologics with new mechanisms of action and potentially some biologics that might have prolonged effects and so that the dosing regimen can be reduced and patients don't need as many injections. So molecules that inhibit OX40 or other targets or even some molecules that inhibit the same targets that dupilumab and other current biologics inhibit, like interleukin-4, interleukin-13. If they're l- prolonged half-life molecules, they might be able to work for longer and save patients some injections.
In terms of oral agents, there are some really new molecules we've seen some interesting data for. For example, presented at, the recent AAD meeting at the late breakers, there was a presentation on a STAT-6 degrader, and I thought that was really interesting. So, that's still early phase. We still need to see, you know, larger studies on those, but looking forward to seeing what comes next.
